Meet Our Featured Speakers
GLOBAL FORUM FOR MRNA-BASED THERAPEUTICS AND DRUG DEVELOPMENT
Welcome to mRNA Conference USA 2026, where global pharmaceutical and biotech leaders join industry experts to explore breakthroughs in mRNA therapeutics for vaccines, personalized medicine, and beyond.
The event explores the role of mRNA technology in developing novel treatments, covering the full spectrum from R&D to clinical trials, large-scale manufacturing, and commercialization. It highlights advancements in RNA modification, therapeutic delivery systems, and vaccine development, and showcases the latest progress in mRNA, siRNA, and miRNA-based therapeutics.
Join us to explore next-generation mRNA therapeutics, gain valuable insights, and connect with peers to help shape the future of medicine.
key topics for
Future of mRNA-based therapeutics for infectious diseases and beyond
Explore the potential of mRNA therapeutics as a transformative new class of drugs.
Breakthrough research in mRNA, siRNA, and miRNA-based therapeutics
Gain insights into how advancements in mRNA, siRNA, and miRNA are shaping the future of therapeutic applications.
Challenges in scaling mRNA vaccines manufacturing for global distribution
Analyze advanced methods for the rapid development and large-scale distribution of vaccines in response to pandemics.
Latest advancements in mRNA formulation and delivery technologies
Discover the latest advancements in therapeutic mRNA delivery as they progress from the laboratory to patient treatment.
AI and ML-driven approaches to enhance mRNA therapeutic design
Learn how advanced AI and machine learning algorithms, combined with data analytics, are accelerating therapeutic design and revealing new insights.
Regulatory and compliance considerations in mRNA clinical development
Understand key regulatory and compliance considerations for the approval of mRNA therapeutics.
INDUSTRY TOPICS
NETWORKING EVENTS
LEADING EXPERTS
Q&A SESSIONS
Latest News
INNOVATION
11 Feb 2026
Britain’s Bet On Better RNA FactoriesPARTNERSHIPS
10 Feb 2026
Moderna and Recordati Bet on mRNA Beyond VaccinesMARKET TRENDS
5 Feb 2026
mRNA Deals Push the Industry Beyond VaccinesPARTNERSHIPS
3 Feb 2026
BioNTech–CureVac Deal Marks a New Era for mRNA
GSK’s $2.2B Bet Signals a New Phase in Allergy Drug Races

PARTNERSHIPS
20 Jan 2026
GSK’s acquisition of RAPT spotlights late-stage allergy drugs, hints at a cautious M&A revival, and raises the stakes in immunology
they've attended our events
Expert Speakers
Kok-Seong Lim
Independent Consultant
Craig Martin
University of Massachusetts
Pintu Kanjilal
Strand Therapeutics
Past Attendees
Sanofi
28 Capital
Mayo Clinic
Arcturus Therapeutics
Crafton Biotechnology
Tessera Therapeutics
TriLink BioTechnologies
Standard BioTools
University of Michigan














